| Edward Long, | |
|
2402 E Main St, Suite 8, Merrill, WI 54452-2702 | |
| (715) 539-0441 | |
| Not Available |
| Full Name | Edward Long |
|---|---|
| Gender | Male |
| Speciality | Dentist - General Practice |
| Location | 2402 E Main St, Merrill, Wisconsin |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235321555 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1223G0001X | Dentist - General Practice | 5766015 (Wisconsin) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Edward Long, 2402 E Main St, Suite 8, Merrill, WI 54452-2702 Ph: () - | Edward Long, 2402 E Main St, Suite 8, Merrill, WI 54452-2702 Ph: (715) 539-0441 |
News Archive
Mayo Clinic researchers, working with colleagues at the University of Minnesota and University of Pittsburgh, are the first to describe a new role for a specialized cell of the immune system in children suffering from a rare muscle-damaging disease known as juvenile dermatomyositis (JDM).
The Cancer Research Institute, a nonprofit organization dedicated to the development of immune system-based treatments for cancer, announced today its celebration of a significant new breakthrough in the treatment of melanoma, the deadliest form of skin cancer. The new treatment, a cancer immunotherapy created by Cancer Research Institute Scientific Advisory Council Associate Director James P. Allison, Ph.D., is designed to "take the brakes off the immune system," and is the first treatment ever proven to extend life for patients whose melanomas are unresponsive to existing cancer therapies.
A comprehensive review of four decades of national homicide data show important gender differences and trends among homicide victims and offenders in the U.S., related to prevalence and the characteristics of the crimes and the men and women involved.
BELLUS Health Inc. and Celtic Therapeutics announced today that a global confirmatory phase III clinical study was initiated on December 14, 2010 for KIACTA™ (eprodisate). KIACTA™ is a drug candidate being developed for the treatment of AA amyloidosis, a life-threatening orphan disease that occurs in patients with long-lasting inflammatory conditions, most commonly due to rheumatoid arthritis. The study is designed to confirm the safety and efficacy of KIACTA™ in preventing renal function decline in patients with AA amyloidosis.
Cholesterol contributes to atherosclerosis - a condition that greatly increases the risk of heart attack and stroke - by suppressing the activity of a key protein that protects the heart and blood vessels, researchers at the Saint Louis University School of Medicine have found.
› Verified 2 days ago
Dr. Jennifer Lind Freyer, DDS Dentist Medicare: Medicare Enrolled Practice Location: 601 S Center Ave, Merrill, WI 54452 Phone: 715-539-8181 | |
Dr. Olga Simona Nasea, D.D.S. Dentist Medicare: Medicare Enrolled Practice Location: 3424 E Main St, Merrill, WI 54452 Phone: 715-536-8345 | |
Matthew Joseph Welch, D.D.S. Dentist Medicare: Medicare Enrolled Practice Location: 3424 E Main St, Merrill, WI 54452 Phone: 715-536-8345 | |
Drew Aaron Bertelson, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 3424 E Main St, Merrill, WI 54452 Phone: 715-536-7104 | |
Dr. Adam Manteuffel, D.D.S. Dentist Medicare: Medicare Enrolled Practice Location: 3424 E Main St, Merrill, WI 54452 Phone: 715-536-8345 | |
Dr. Mark L. Mehlos, D.D.S. Dentist Medicare: Not Enrolled in Medicare Practice Location: 110 N Prospect St, Merrill, WI 54452 Phone: 715-536-3525 |